CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE...And Exclusive License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • California
THIS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of April 1, 2013 (the “Effective Date”), by and between AGENSYS, INC., a corporation organized and existing under the laws of the State of California (“Agensys”) and AMBRX, INC., a corporation organized and existing under the laws of the State of Delaware (“Ambrx”).
RESEARCH COLLABORATION, OPTION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and AMBRX, INC.And Exclusive License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations
THIS RESEARCH COLLABORATION, OPTION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of June 13, 2012 (the “Effective Date”), by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey, (“Merck”) and AMBRX, INC., a corporation organized and existing under the laws of the State of Delaware (“Ambrx”).
AND EXCLUSIVE LICENSE AGREEMENTAnd Exclusive License Agreement • August 9th, 2010 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of May 4, 2010 (the “Restated Effective Date”), by and among ARIAD Pharmaceuticals, Inc. a Delaware corporation with offices at 26 Landsdowne Street, Cambridge, Massachusetts 02139 (“ARIAD”), and Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.), a Corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100 (“MERCK”). Each of MERCK and ARIAD is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO DEVELOPMENT COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTAnd Exclusive License Agreement • November 12th, 2019 • Molecular Templates, Inc. • Pharmaceutical preparations
This First Amendment to Development Collaboration and Exclusive License Agreement (this “Amendment”) is made and entered into as of July 18, 2019 (the “Amendment Effective Date”) by and between Molecular Templates, Inc., a Delaware corporation, having its principal place of business at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTEM”), and Millennium Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Takeda”). MTEM and Takeda may be referred to herein collectively as the “Parties” and individually as a “Party.”
